Abstract 5226: TPX-0131: a next generation macrocyclic ALK inhibitor that overcomes ALK resistant mutations refractory to current approved ALK inhibitors - Cui, J J; Rogers, E; Zhai, D (Cancer Res, 2020)
(16, Supplement):